The nano-weapons are in the advanced preclinical stage, which means they are at least a year away from being presented for approval

GUANGZHOU, GUANGDON, CHINA, June 29, 2018 /EINPresswire.com/ -- Nano Vivere (ISIN: CN0024013913), a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that it has received a $1 million grant from the Cancer Institute of Prevention to advance its research of tumor nano-immunology to treat cancers of the brain, breast, lung and other organs.
“Our goal is to improve the body’s immune system so it can block tumors from forming,” Dr. Don T. Leung, co-founder and Chief Executive Officer said. “This new grant will allow us to continue developing a new generation of drugs that will have the ability to improve the pharmaceutical and pharmacological properties of anti-cancer drugs, increase the efficacy of cancer treatment and deliver multiple types of therapeutics for combination therapy.”
Dr. Don T. Leung, co-founder and Chief Executive Officer also director of the Nanomedicine Research Center has received four previous grants to support his work. In all, the institute has awarded him $10 million.
Dr. Don T. Leung and his team at Nano Vivere, work to improve the treatment of brain, breast and lung cancers, focusing in particular on forms of the disease that have a poor prognosis or are largely incurable with current therapies. Dr. Don T. Leung said the goal of engineering and producing nanomedicines is to reduce the toxic effect of anti-cancer drugs by delivering them directly to cancer cells, leaving non-tumor cells intact.
Nanodrugs have been shown to effectively treat tumors that originate in the brain, as well as breast and brain cancers that metastasize from the lungs and breasts. The nano imaging MRI diagnostic agents have the potential to replace invasive tissue biopsies, particularly in patients who have multiple brain lesions.
Ultimately, Dr. Don T. Leung and his team hope to bring the novel imaging and treatment drugs to clinical practice with patients and that the side effects of the treatments will be significantly reduced.

About Nano Vivere (ISIN: CN0024013913)

Nano Vivere is a late stage clinical company, pioneering nanomedicine that is following its unique path: a new way to treat patients thanks to nanophysics delivered at the cell’s nucleus. The company’s technology is based on proprietary technologies and patents and it operates worldwide from the headquarters based in Guangzhou. Nano Vivere is led by a highly trained and distinguished team of experts who have demonstrated success in the combined fields medicine, biologics, neuroscience, and nanotechnology along with the specialized business development track record requisite for the launch of cutting-edge medical technologies.

Jackline Tang
Nano Vivere
13057400750
email us here